Investors in Ocular Therapeutix Inc (Symbol: OCUL) saw new options begin trading this week, for the June 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Investors in Ocular Therapeutix Inc (Symbol: OCUL) saw new options become available today, for the April 2026 expiration. One of the key data points that goes into the price an option buyer is willing ...

Wondering if Ocular Therapeutix at around US$7.78 is offering fair value right now, or if the recent volatility is masking a better entry point for long term investors. The stock has seen a 12.4% ...

Ocular Therapeutix Inc (NASDAQ:OCUL) shares are trading lower by 13.3% to $7.63 Monday afternoon after the company reported worse-than-expected first-quarter financial results. What To Know: Ocular ...

Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 8.6% in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about ...

Net revenue (GAAP) dropped 18.1% year-over-year in Q2 2025, as reimbursement pressure continued to impact results despite increased unit sales for DEXTENZA. Research and development expenses surged 76 ...

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

We recently published 11 Stocks Failing to Keep up With The Market. Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the top performers on Tuesday. Ocular Therapeutix saw its share prices drop by 6.7 ...

Ocular Therapeutix (OCUL) shares ended the last trading session 6.1% higher at $11.07. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.